Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-Hydroxybenzaldehyde O-(cyclohexylcarbonyl)oxime is an experimental small molecule compound belonging to the class of organic compounds known as 1-hydroxy-2-unsubstituted benzenoids, specifically phenols with a cyclohexanecarbonyl oxime moiety. It has been studied for its ability to inhibit macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine implicated in immune response and various diseases. The compound exhibits weak hERG inhibition and is not ready biodegradable. Its primary mechanism of action is as an inhibitor of MIF, with reported IC50 values in the low micromolar range[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-hydroxybenzaldehyde O-(cyclohexylcarbonyl)oxime.